FibroBiologics (FBLG) Accounts Payables (2022 - 2026)
FibroBiologics (FBLG) posted quarterly Accounts Payables of $1.8 million for Q2 2026, up 1.11% year-over-year from $1.8 million in Q2 2025, and up 114.24% on a QoQ basis from $850000.0 in Q1 2026.
FibroBiologics (FBLG) Accounts Payables (2022 - 2026) Analysis & Trends
FibroBiologics has reported Accounts Payables for 5 years, with the latest figure at $1.8 million in Q2 2026.
- Accounts Payables for Q2 2026 came in at $1.8 million, up 1.11% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.8 million (up 1.11% YoY), and the FY2025 annual result was $945000.0, down 64.96% from the prior year.
- Accounts Payables advanced to $1.8 million in Q2 2026, from $850000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $2.7 million in Q4 2024 and troughed at $758000.0 in Q4 2022.
- A 5-year average of $1.3 million and a median of $1.2 million in 2024 frame the typical range for Accounts Payables.
- The widest annual swing landed in 2023, when Accounts Payables soared 90.5%; it then tumbled 64.96% in 2025.
- A 5-year view of Accounts Payables shows it stood at $758000.0 in 2022, then soared by 90.5% to $1.4 million in 2023, then jumped by 86.77% to $2.7 million in 2024, then tumbled by 64.96% to $945000.0 in 2025, then soared by 92.7% to $1.8 million in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $1.8 million in Q2 2026, $850000.0 in Q1 2026, and $945000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - | 1.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.82 Mn |
| Mar 31, 2026 | 850,000.00 |
| Dec 31, 2025 | 945,000.00 |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Dec 31, 2024 | 2.70 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 814,000.00 |
| Dec 31, 2023 | 1.44 Mn |
| Dec 31, 2022 | 758,000.00 |